Estimating Relative Fracture Reduction of Romosozumab versus Teriparatide for Postmenopausal Osteoporosis Using Bone Mineral Density Outcomes

被引：0
|
作者：
Johnson, Benjamin [1 ]
McClung, Michael [2 ]
Silverman, Stuart [3 ]
Gandra, Shravanthi [4 ]
Timoshanko, Jennifer [5 ]
Stollenwerk, Bjorn [6 ]
机构：
[1] Amgen Ltd, Cambridge, England
[2] Oregon Osteoporosis Ctr, Portland, OR USA
[3] Cedars Sinai, Los Angeles, CA USA
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] UCB Pharma Ltd, Slough, Berks, England
[6] Amgen GmbH, Risch Rotkreuz, Switzerland
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-646
引用
收藏
页码：248 / 248
页数：1
相关论文
共 50 条
  • [1] IMPACT OF ROMOSOZUMAB ON BONE MINERAL DENSITY IN POSTMENOPAUSAL OSTEOPOROSIS
    Azharuddin, M.
    Sharma, M.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S425 - S425
  • [2] Impact of romosozumab on bone mineral density in postmenopausal osteoporosis
    Azharuddin, Md
    Sharma, Manju
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 330 - 330
  • [3] Postmenopausal osteoporosis with vertebral fracture: teriparatide vs romosozumab
    Torres, Manuel Munoz
    [J]. REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2023, 15 (02)
  • [4] Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis
    Gallagher, J. C.
    Rosen, C. J.
    Chen, P.
    Misurski, D. A.
    Marcus, R.
    [J]. BONE, 2006, 39 (06) : 1268 - 1275
  • [5] Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
    Hagino, H.
    Tanaka, K.
    Silverman, S.
    McClung, M.
    Gandra, S. R.
    Charokopou, M.
    Adachi, K.
    Johnson, B.
    Stollenwerk, B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (10) : 2011 - 2021
  • [6] Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
    H. Hagino
    K. Tanaka
    S. Silverman
    M. McClung
    S. R. Gandra
    M. Charokopou
    K. Adachi
    B. Johnson
    B. Stollenwerk
    [J]. Osteoporosis International, 2021, 32 : 2011 - 2021
  • [7] Effects of romosozumab on low bone mineral density or osteoporosis in postmenopausal women: a systematic review
    Chen, Wenxiang
    Yang, Huiying
    Jiang, Xuesheng
    [J]. ANNALS OF JOINT, 2020, 5 (02):
  • [8] Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials
    Han, S-L.
    Wan, S-L.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (02) : 199 - 209
  • [9] Cost-effectiveness of Romosozumab versus Teriparatide for Severe Postmenopausal Osteoporosis in Japan
    Hagino, Hiroshi
    Tanaka, Kiyoshi
    McClung, Michael
    Silverman, Stuart
    Gandra, Shravanthi
    Charokopou, Mata
    Adachi, Kenji
    Johnson, Benjamin
    Stollenwerk, Bjorn
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 256 - 256
  • [10] THE USE OF TERIPARATIDE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - EXPERIENCE OF USING BONE MARKERS AND BONE MINERAL DENSITY TO MONITOR RESPONSE
    Hollick, Rosemary J.
    Reid, David M.
    Black, Alison J.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S574 - S575
12345